Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Depression In Patients With Charcot-Marie-Tooth Disease Type 1A (CMT1A): Findings From A Real-World Digital Study
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
Depression In Patients With Charcot-Marie-Tooth Disease Type 1A (CMT1A): Findings From A Real-World Digital Study
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
Depression In Patients With Charcot-Marie-Tooth Disease Type 1A (CMT1A): Findings From A Real-World Digital Study
Youcef Boutalbi
Abstract
Discussion Forum (0)
Depression In Patients With Charcot-Marie-Tooth Disease Type 1A (CMT1A): Findings From A Real-World Digital Study
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
Depression In Patients With Charcot-Marie-Tooth Disease Type 1A (CMT1A): Findings From A Real-World Digital Study
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
Poster No: 1029
Presenter: Youcef Boutalbi
Institution: Pharnext
Introduction: This analysis aimed to examine patient-reported diagnosis of, and consequences associated with, depression among Charcot-Marie-Tooth disease type 1A (CMT1A) patients in European and US real-world practice.
Methods: Adults with CMT1A were recruited to an ongoing international observational study exploring the real-world impact of CMT. Data were collected via CMT&Me, a bespoke digital app developed for this study, through which participants were asked questions on demographic and employment variables. This interim analysis examined participants (n=937) from France, Germany, Italy, Spain, the UK and the US.
Results: Thirty-eight percent of participants (n=238/628 who reported other medical conditions) reported having been diagnosed with depression in addition to CMT1A; higher than in the general population. Of these, 54% (n=112/208 who also reported symptom severity) and 35% (n=72/208) reported moderate or severe CMT1A symptom severity respectively. Forty-three percent of participants diagnosed with depression (n=102/238) reported that they used, or had previously used, antidepressants. Reported diagnosis of depression varied considerably by country. Highest rates were among participants in the US and UK (48% and 40% respectively – of which 17% (n=17/103) and 38% (n=25/66) reported severe symptom severity respectively), while lowest rates were among participants in France and Italy (29% and 18% respectively – of which 53% (n=9/17) and 31% (n=5/16) reported severe symptom severity respectively). Of participants who responded to the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) instrument (n=685), 62% reported concerns with anxiety/depression.
Conclusions: Over a third of participants reported diagnosis of depression in addition to CMT1A. This is not surprising for a disease with this symptom burden; however, depression itself as a comorbid condition represents significant disease burden and can affect treatment and outcomes for CMT1A – this warrants further analysis and exploration.
References: No
References 1:
References 2:
References 3:
References 4:
Grant Support:
Keywords: Charcot-Marie-Tooth disease, Depression
{{ help_message }}
{{filter}}